期刊文献+

右旋糖酐联合活血化瘀方治疗肺气肿100例 被引量:1

Clinical Observation of Dextran Combined with Huoxue Huayu Prescription on the Treatment of Emphysema 100 Cases
下载PDF
导出
摘要 目的对右旋糖酐联合活血化瘀方治疗肺气肿临床效果进行分析。方法选取2011年6月—2014年12月抚州市第一中医院治疗肺气肿患者200例,分别进行常规活血化瘀治疗100例,为常规组;右旋糖酐治疗100例,为联合组,对治疗效果进行分析。结果联合组临床总有效率、2疗程治疗临床症状积分、临床症状缓解时间、住院治疗时间等均明显优越于常规治疗组患者,差异性显著,存在统计学意义(P<0.05)。200例患者均没有发生因治疗用药导致严重药物过敏和药物安全事件发生。结论对于肺气肿患者应用常规活血化瘀方剂治疗基础上联合右旋糖酐口服治疗,可有效地增加临床治疗效果,促进患者康复,缩短临床症状缓解时间和住院治疗时间,药物安全性较高,对于肺气肿患者可针对性地应用治疗。 Objective To study the clinical effect of dextran combined with Huoxue Huayu prescription on the treatment of emphysema.Methods 200 cases of emphysema patients in our hospital from June 2011 to December 2014 were selected. The conventional group of100 cases was given routine Huoxue Huayu treatment; the combined group of 100 cases received dextran treatment, the curative effect was analyzed. Results The total clinical effective rate, course of treatment clinical symptom score, clinical symptom remission time and hospitalization time of the combined group were obviously superior to the conventional treatment group, and had significant differences( P 〈0.05). Conclusion For patients with emphysema, routine Huoxue Huayu treatment on the basis of dextran oral treatment can effectively increase the clinical treatment effect, promote the rehabilitation of patients, and shorten clinical symptom remission time and hospitalization time. It is safe and pertinency for patients with emphysema.
作者 陈祖明
出处 《中国中医药现代远程教育》 2015年第8期61-62,共2页 Chinese Medicine Modern Distance Education of China
关键词 右旋糖酐 活血化瘀 肺气肿 中西医结合疗法 dextran Huoxue Huayu emphysema therapy of integrated medicine
  • 相关文献

参考文献6

二级参考文献44

  • 1刘海波,陆爱军,刘冰,周家驹.通过共有化合物建立中药药效和现代药理间的联系[J].中国中药杂志,2005,30(1):75-78. 被引量:5
  • 2吴晓玲,曾维政,蒋明德,王丕龙.肝纤维化的信号转导通路[J].世界华人消化杂志,2006,14(22):2223-2228. 被引量:33
  • 3宋崇顺,田金洲,王永炎,任映,尹军祥,时晶,孙海芸,杨金铎.大分子葡萄糖酐所致血瘀模型小鼠中偶氮蓝渗出量与血瘀程度的相关性[J].中国实验动物学报,2007,15(2):108-111. 被引量:2
  • 4Weinacker A B,Vaszar L T.Acute respiratory distress syndrome:physiology and new management strategies[J].Ann Rev Med,2001,52:221-237. 被引量:1
  • 5Lotersztajn S, Julien B, Teixeira-Clerc F, Grenard P, Mallat A. Hepatic fibrosis: Molecular mechanisms and drug targets. Annu Rev Pharmacol Toxicol, 2005, 45:605-628. 被引量:1
  • 6Stickel F, Schuppan D. Herbal medicine in the treatment of liver diseases. Dig Liver Dis, 2007, 39(4): 293-304. 被引量:1
  • 7Friedman SL, Roll F J, Boyles J, Bissell DM. Hepatic lipocytes: The principal collagen-producing cells of normal rat liver. Proc Natl Acad Sci USA, 1985, 82 (24): 8681 -8685. 被引量:1
  • 8Kisseleva T, Brenner DA. Role of hepatic stellate cells in fibrogenesis and the reversal of fibrosis. J Gastroenterol Hepatol, 2007, 22(Suppl 1): $73-78. 被引量:1
  • 9Brenner DA, Alcorn JM. Therapy for hepatic fibrosis. Semin Liver Dis, 1990, 10(1): 75-73. 被引量:1
  • 10Liu P, Hu YY, Liu C, Xu LM, Liu CH, Sun KW, Hu DC, Yin YK, Zhou XQ, Wan MB, Cai X, Zhang ZQ, Ye J, Zhou RX, He J, Tang BZ. MulUcenter clinical study on Fuzhenghuayu capsule against liver fibrosis due to chronic hepatitis B. World J Gastroenterol, 2005, 11 (19): 2892-2899. 被引量:1

共引文献152

同被引文献5

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部